OXFORD - By announcing his intention to float Evotec BioSystems AG on the Neuer Markt next month, company co-founder and CEO Karsten Henco is hoping not to be swimming upstream. Instead, he is aiming to repeat the success of Qiagen N.V. (NMarkt:QIA; QGENF, Venlo, the Netherlands), a company he also co-founded in 1984.

The long-anticipated flotation would raise E50-E55 million ($53-$58 million) by selling 4 million shares on the Frankfurt exchange for growth companies, which would value Evotec (Hamburg, Germany) at about E143 million ($151 million) (see B11).